|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||6.47 - 6.47|
|52 Week Range||6.47 - 6.47|
|Beta (5Y Monthly)||0.05|
|PE Ratio (TTM)||6.66|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, has filed its 2020 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2020. The Company also reported its unaudited financial results for the fourth quarter ended December 31, 2020.
Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the third production line of CoronaVac®, its COVID-19 vaccine, was completed and put into commercial production. Including this new production line, Sinovac’s annual capacity of CoronaVac® has reached 2 billion doses. At this time, over 200 million doses of CoronaVac have been delivered to over 20 countries, including China. It is estimated that over 100 million doses of CoronaVac have been administered during the vaccination rollout in different countries. The safety and effectiveness of CoronaVac® has been proven gradually along with the rollout of the vaccination around the world.
Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2021 to February 22, 2022.